HC Wainwright & Co. Downgrades Atara Biotherapeutics to Neutral
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Robert Burns has downgraded Atara Biotherapeutics from Buy to Neutral.
November 09, 2023 | 12:46 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Atara Biotherapeutics has been downgraded from Buy to Neutral by HC Wainwright & Co.
The downgrade from Buy to Neutral by a reputable analyst could potentially lead to a decrease in the stock price of Atara Biotherapeutics in the short term as it may influence investor sentiment and decision making.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100